HRP20161514T1 - Uporaba derivata pirazola u liječenju akutnih pogoršanja kronične opstruktivne plućne bolesti - Google Patents

Uporaba derivata pirazola u liječenju akutnih pogoršanja kronične opstruktivne plućne bolesti Download PDF

Info

Publication number
HRP20161514T1
HRP20161514T1 HRP20161514TT HRP20161514T HRP20161514T1 HR P20161514 T1 HRP20161514 T1 HR P20161514T1 HR P20161514T T HRP20161514T T HR P20161514TT HR P20161514 T HRP20161514 T HR P20161514T HR P20161514 T1 HRP20161514 T1 HR P20161514T1
Authority
HR
Croatia
Prior art keywords
cyanobenzoyl
methylbenzamide
pyrazol
cyclopropyl
amino
Prior art date
Application number
HRP20161514TT
Other languages
English (en)
Croatian (hr)
Inventor
Paul Andrew FORD
Original Assignee
Mereo Biopharma 1 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Limited filed Critical Mereo Biopharma 1 Limited
Publication of HRP20161514T1 publication Critical patent/HRP20161514T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20161514TT 2012-03-20 2013-03-19 Uporaba derivata pirazola u liječenju akutnih pogoršanja kronične opstruktivne plućne bolesti HRP20161514T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
EP13710851.0A EP2827860B1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
HRP20161514T1 true HRP20161514T1 (hr) 2016-12-30

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161514TT HRP20161514T1 (hr) 2012-03-20 2013-03-19 Uporaba derivata pirazola u liječenju akutnih pogoršanja kronične opstruktivne plućne bolesti

Country Status (29)

Country Link
US (2) US9339491B2 (enExample)
EP (1) EP2827860B1 (enExample)
JP (1) JP6091593B2 (enExample)
KR (1) KR101793777B1 (enExample)
CN (1) CN104203234B (enExample)
AU (1) AU2013237503B2 (enExample)
BR (1) BR112014023107B1 (enExample)
CA (1) CA2866108C (enExample)
CL (1) CL2014002471A1 (enExample)
CY (1) CY1118327T1 (enExample)
DK (1) DK2827860T3 (enExample)
ES (1) ES2605942T3 (enExample)
HR (1) HRP20161514T1 (enExample)
HU (1) HUE032004T2 (enExample)
IL (1) IL234537A (enExample)
LT (1) LT2827860T (enExample)
MA (1) MA37455B1 (enExample)
MX (1) MX351996B (enExample)
NZ (1) NZ628392A (enExample)
PH (1) PH12014502107B1 (enExample)
PL (1) PL2827860T3 (enExample)
PT (1) PT2827860T (enExample)
RU (1) RU2625762C2 (enExample)
SG (1) SG11201404941WA (enExample)
SI (1) SI2827860T1 (enExample)
TN (1) TN2014000350A1 (enExample)
TW (1) TWI583381B (enExample)
WO (1) WO2013139809A1 (enExample)
ZA (1) ZA201405871B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) * 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
CN114141383A (zh) * 2021-12-17 2022-03-04 湖南大学 慢阻肺智能护理方法、装置及系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NZ628392A (en) 2016-06-24
TWI583381B (zh) 2017-05-21
US20150031736A1 (en) 2015-01-29
MX351996B (es) 2017-11-06
CA2866108A1 (en) 2013-09-26
IL234537A (en) 2016-09-29
ZA201405871B (en) 2016-01-27
LT2827860T (lt) 2016-12-12
PH12014502107B1 (en) 2019-11-27
SI2827860T1 (sl) 2017-01-31
JP2015510916A (ja) 2015-04-13
MA37455B1 (fr) 2017-03-31
CY1118327T1 (el) 2017-06-28
EP2827860B1 (en) 2016-10-26
PT2827860T (pt) 2016-12-20
EP2827860A1 (en) 2015-01-28
PH12014502107A1 (en) 2014-12-10
CA2866108C (en) 2017-03-07
KR101793777B1 (ko) 2017-11-03
HK1200352A1 (en) 2015-08-07
US20160243081A1 (en) 2016-08-25
SG11201404941WA (en) 2014-10-30
TW201343162A (zh) 2013-11-01
KR20140146073A (ko) 2014-12-24
CN104203234B (zh) 2017-06-13
MX2014011291A (es) 2014-10-13
CN104203234A (zh) 2014-12-10
US9339491B2 (en) 2016-05-17
BR112014023107A2 (enExample) 2017-06-20
TN2014000350A1 (en) 2015-12-21
CL2014002471A1 (es) 2015-01-09
AU2013237503A1 (en) 2014-09-25
RU2625762C2 (ru) 2017-07-18
RU2014141893A (ru) 2016-05-10
BR112014023107B1 (pt) 2021-08-10
WO2013139809A1 (en) 2013-09-26
MA37455A1 (fr) 2016-08-31
DK2827860T3 (en) 2016-12-12
ES2605942T3 (es) 2017-03-17
PL2827860T3 (pl) 2017-09-29
HUE032004T2 (en) 2017-08-28
AU2013237503B2 (en) 2016-05-26
JP6091593B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
NZ628392A (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP2013014622A5 (enExample)
JP2016518337A5 (enExample)
JP2016515522A5 (enExample)
JP2015510916A5 (enExample)
JP2015525757A5 (enExample)
CU20150020A7 (es) Composición farmacéutica recubierta que contiene regorafenib
JP2013507408A5 (enExample)
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
JP2013166781A5 (enExample)
JP2019528267A5 (enExample)
CL2013002996A1 (es) Uso de aclidinio o sus sales o cualquiera de sus estereoisomeros o mezcla de estereoisomeros, o una sal farmeceuticamente aceptable o solvato del mismo para la preparacion de un medicemnto util en mejorar la calidad del sueño en enfermos respiratorios.
MX385717B (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
JP2014520874A5 (enExample)
PL3369429T3 (pl) Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa
JP2015129124A5 (enExample)
JP2013542262A5 (enExample)
CN104870437A (zh) 三嗪化合物、其药用盐、异构体或水合物及其药物组合物
HUE037541T2 (hu) Szildenafil-citrát gyógyászati kompozíciója szuszpenzió formájában orális alkalmazásra
HRP20230105T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti
JP2018510153A5 (enExample)
ES2468665B1 (es) Composición farmacéutica de sulfato de condroitina y celecoxib
PL2676661T3 (pl) Podawana doustnie trójwarstwowa pigułka o przedłużonym uwalnianiu zawierająca tamsulosynę lub jej farmaceutycznie dopuszczalną sól
CN302277699S (zh) 包装软管(尤卓尔)